These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 20624047

  • 1. DNA vaccines for the treatment of prostate cancer.
    Alam S, McNeel DG.
    Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 4. DNA vaccines for cancer.
    Boyd D, Hung CF, Wu TC.
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 6. Prostate cancer immunotherapy.
    McNeel DG.
    Curr Opin Urol; 2007 May 15; 17(3):175-81. PubMed ID: 17414515
    [Abstract] [Full Text] [Related]

  • 7. PSA-based vaccines for the treatment of prostate cancer.
    Madan RA, Gulley JL, Arlen PM.
    Expert Rev Vaccines; 2006 Apr 15; 5(2):199-209. PubMed ID: 16608420
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
    Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG.
    Vaccine; 2006 Jan 16; 24(3):293-303. PubMed ID: 16115700
    [Abstract] [Full Text] [Related]

  • 9. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr 16; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 10. Vaccine therapy for prostate cancer.
    Sonpavde G, Spencer DM, Slawin KM.
    Urol Oncol; 2007 Apr 16; 25(6):451-9. PubMed ID: 18047951
    [Abstract] [Full Text] [Related]

  • 11. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF, Drake CG.
    Surg Oncol Clin N Am; 2007 Oct 16; 16(4):861-71, x. PubMed ID: 18022549
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapeutics in development for prostate cancer.
    Harzstark AL, Small EJ.
    Oncologist; 2009 Apr 16; 14(4):391-8. PubMed ID: 19342474
    [Abstract] [Full Text] [Related]

  • 13. DNA vaccines: an historical perspective and view to the future.
    Liu MA.
    Immunol Rev; 2011 Jan 16; 239(1):62-84. PubMed ID: 21198665
    [Abstract] [Full Text] [Related]

  • 14. Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Slovin SF.
    Cancer J; 2008 Jan 16; 14(1):26-34. PubMed ID: 18303480
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic vaccines for prostate cancer.
    Cha E, Fong L.
    Curr Opin Mol Ther; 2010 Feb 16; 12(1):77-85. PubMed ID: 20140819
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S.
    Immunol Lett; 2005 Jun 15; 99(1):85-93. PubMed ID: 15894116
    [Abstract] [Full Text] [Related]

  • 19. DNA vaccines for prostate cancer.
    Zahm CD, Colluru VT, McNeel DG.
    Pharmacol Ther; 2017 Jun 15; 174():27-42. PubMed ID: 28185916
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.